HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Immix Biopharma (NASDAQ:IMMX) and maintained a price target of $7, indicating confidence in the company's future performance.
October 03, 2024 | 10:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Immix Biopharma and maintained a $7 price target, suggesting positive expectations for the company's stock performance.
The reiteration of a Buy rating and maintenance of a $7 price target by HC Wainwright & Co. indicates strong confidence in Immix Biopharma's potential, likely leading to positive investor sentiment and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100